TACSTD2 and breast carcinoma: Similarly, Ambrogi et al. analyzed the association between Trop-2 expression and outcomes of 702 breast cancer patients, and found that patients with higher membranous expression of Trop-2 had a worse prognosis (overall survival and disease relapse) [32].